Propanc Biopharma, Inc. Common Stock (PPCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($9.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Propanc Biopharma, Inc. Common Stock to measure how much of total assets are equity-financed.
Propanc Biopharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PPCB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Propanc Biopharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Site Group International Ltd
AU:SIT
|
0.088x |
|
Limas Indonesia Makmur Tbk
JK:LMAS
|
0.000x |
|
Percheron Therapeutics Ltd
AU:PER
|
-0.716x |
|
Jeffs' Brands Ltd
NASDAQ:JFBR
|
-0.295x |
|
Erayak Power Solution Group Inc. Class A Ordinary Shares
NASDAQ:RAYA
|
-0.068x |
|
China Aoyuan Group Limited
F:47C
|
-0.067x |
|
Appulse Corp
V:APL
|
0.003x |
|
Olivers Real Food Ltd
AU:OLI
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Propanc Biopharma, Inc. Common Stock (PPCB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.91 Million | $-405.17K | -0.029x | -111.77% |
| 2024-06-30 | $-3.78 Million | $-935.12K | 0.247x | -30.21% |
| 2023-06-30 | $-3.12 Million | $-1.11 Million | 0.355x | -25.36% |
| 2022-06-30 | $-3.02 Million | $-1.44 Million | 0.475x | +27.23% |
| 2021-06-30 | $-3.07 Million | $-1.15 Million | 0.373x | -26.50% |
| 2020-06-30 | $-3.64 Million | $-1.85 Million | 0.508x | +6.05% |
| 2019-06-30 | $-4.30 Million | $-2.06 Million | 0.479x | +48.50% |
| 2018-06-30 | $-6.75 Million | $-2.18 Million | 0.323x | -18.43% |
| 2017-06-30 | $-5.44 Million | $-2.15 Million | 0.395x | -78.87% |
| 2016-06-30 | $-2.57 Million | $-4.80 Million | 1.871x | +300.52% |
| 2015-06-30 | $-3.05 Million | $-1.43 Million | 0.467x | +190.54% |
| 2014-06-30 | $-1.41 Million | $-226.44K | 0.161x | -0.95% |
| 2013-06-30 | $-792.48K | $-128.65K | 0.162x | -48.72% |
| 2012-06-30 | $-537.92K | $-170.28K | 0.317x | +338.36% |
| 2011-06-30 | $10.51 Million | $-1.40 Million | -0.133x | -112.96% |
| 2010-06-30 | $-186.90K | $-191.51K | 1.025x | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more